Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine (Q36980823)

17 August 2017

1 reference

title

Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine (English)

1 reference

17 August 2017

1 reference

Nashan D

1 reference

17 August 2017

Müller ML

1 reference

17 August 2017

Grabbe S

1 reference

17 August 2017

Wustlich S

1 reference

17 August 2017

Enk A

1 reference

17 August 2017

language of work or name

1 reference

1 November 2007

1 reference

Journal of the European Academy of Dermatology and Venereology

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

1305-1318

1 reference

Therapy of cutaneous metastases of malignant melanoma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Current therapy for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

The role interferon-alpha in malignant melanoma remains to be defined

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

European approach to the treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

A review of evidence-based treatment of stage IIB to stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Cutaneous melanoma: available therapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

U.K. guidelines for the management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2007.02475.X

Systemic treatments for metastatic cutaneous melanoma.

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001215

Identifiers

DOI

10.1111/J.1468-3083.2007.02475.X

1 reference

17 August 2017

1 reference